How Dietary Fat Could Change CBD Drug Interactions

Cannabidiol (CBD) has become one of the most widely used cannabinoid products for wellness, epilepsy, chronic pain, anxiety, and other conditions. While researchers have long known that CBD can interact with certain prescription medications, emerging research suggests there may be another important piece of the puzzle: metabolic health.

A 2026 laboratory study¹ found that the amount of fat present in the liver, and even the lipid-rich environment created by a high-fat diet, could influence how CBD interacts with one of the body’s most important drug-metabolizing enzymes. Their findings highlight an important gap in current knowledge and raises new questions about whether CBD safety studies should include metabolically unhealthy populations rather than relying primarily on healthy volunteers. Let’s dive into this groundbreaking research and the implications it has for patients who use CBD.

Why CBD Drug Interactions Matter

Most medications are broken down by enzymes in the liver before they leave the body. Among the most important of these enzymes is CYP2C19, which helps metabolize several commonly prescribed medications, including certain antidepressants, proton pump inhibitors, anti-seizure medications, and antiplatelet drugs.

CBD is already known to inhibit several cytochrome P450 (CYP450) enzymes, including CYP2C19. When this enzyme is inhibited, medications that depend on it may remain in the bloodstream longer than expected, potentially increasing their effects or side effects.

Previous clinical studies in healthy adults have confirmed that CBD can alter the metabolism of certain medications. However, much less is known about how these interactions may change in people with obesity, fatty liver disease, or other metabolic disorders.

What the Researchers Investigated

To better understand this question, researchers created several laboratory models using human liver microsomes which are tiny structures isolated from donated human liver tissue that contain the enzymes responsible for drug metabolism. The investigators several simulated different metabolic environments, including:

• Healthy liver conditions
• Lipid-rich environments containing triglycerides
• Conditions containing elevated fatty acids
• Liver tissue from donors with metabolic dysfunction-associated steatohepatitis (MASH)

Rather than testing patients, the study examined how these different environments influenced CBD metabolism and its ability to inhibit CYP2C19. While these experiments were conducted in the laboratory, they provide mechanistic insight rather than direct evidence of what happens in people.

Dietary Fat Strengthened CBD’s Enzyme Inhibition

One of the study’s most interesting findings involved the effect of lipids on CYP2C19 activity. Even without CBD present, simulated fatty liver conditions reduced CYP2C19 activity. Exposure to triglycerides lowered enzyme activity by roughly 25%, while fatty acids reduced activity by approximately 68%.

When purified CBD was added to these lipid-rich environments, its ability to inhibit CYP2C19 became even stronger. Compared with normal conditions, triglycerides enhanced CBD’s inhibitory effects by approximately 1.3-fold, while fatty acids increased inhibition by as much as threefold. This suggests that the metabolic environment itself, not simply the CBD dose, may influence how strongly CBD competes with medications for the same metabolic pathway.

Although additional studies in humans are needed, these findings introduce the possibility that dietary fat and liver fat may contribute to the variability seen in CBD drug interactions.

MASH May Slow CBD Clearance

Researchers also examined liver tissue obtained from donors with metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of fatty liver disease characterized by inflammation and liver injury. While CBD inhibited CYP2C19 similarly in liver samples from donors with and without MASH, another important difference emerged as the liver tissue affected by MASH cleared CBD much more slowly.

Specifically, intrinsic clearance through CYP-mediated metabolism was substantially lower in MASH liver tissue than in non-MASH tissue. Clearance through one of CBD’s major glucuronidation pathways was also modestly reduced. If similar effects occur in living patients, CBD could remain in the body longer in individuals with MASH, potentially extending both its therapeutic effects and its interactions with medications. However, this possibility has not yet been confirmed in clinical studies.

Why These Findings Are Important

Current CBD interaction warnings generally focus on the amount of CBD someone consumes and the medications they take. However, this study suggests another factor may deserve attention, the patient’s metabolic health.

People with fatty liver disease or metabolic disorders may process CBD differently than healthy individuals. At the same time, the lipid-rich liver environment itself could influence how CBD and prescription drugs compete for the same metabolizing enzymes.

This does not necessarily mean drug interactions will always become stronger or more dangerous. The human metabolism is far more complex than laboratory models, and many additional factors, including genetics, age, medication dose, liver function, and overall health, also influence how drugs are processed. However, the findings provide a plausible biological explanation for why individuals with metabolic disease might not respond to CBD in exactly the same way as healthy volunteers.

What This Means for CBD Users

For most people, these findings are not a reason to stop using CBD. Instead, they reinforce an important principle already recommended by healthcare professionals, that anyone taking prescription medications should discuss CBD use with their healthcare provider.

Individuals with diagnosed fatty liver disease or MASH should also recognize that researchers are actively investigating whether these conditions alter CBD metabolism. At present, there is not enough clinical evidence to recommend avoiding CBD solely because someone has fatty liver disease. Rather, the research highlights why future studies need to include populations that better reflect real-world patients, many of whom have obesity, metabolic syndrome, fatty liver disease, or diabetes.

The Need for Better CBD Safety Research

Perhaps the most valuable contribution of this study is not a new safety warning but a new research direction. Many clinical drug interaction studies are conducted in healthy volunteers with normal liver function. While these studies establish important baseline information, they may not fully capture what happens in patients living with chronic metabolic disease.

Future investigations should incorporate modified laboratory models, including human liver microsomes and hepatocytes representing hepatic steatosis and MASH, to better understand how CBD and other medications behave in metabolically unhealthy populations. As CBD use continues to grow among people managing chronic health conditions, understanding these differences may become increasingly important for personalized medicine.

Final Thoughts

This preclinical study provides valuable mechanistic insight into how dietary lipids, fatty liver conditions, and metabolic dysfunction may influence CBD metabolism and drug interactions. The findings suggest that both the liver’s lipid environment and diseases such as MASH could alter how CBD inhibits CYP2C19 and how quickly the body clears the cannabinoid.

Importantly, these laboratory findings should not be interpreted as evidence that people with fatty liver disease must avoid CBD. Instead, they identify an important knowledge gap and underscore the need for clinical studies involving metabolically unhealthy populations.

As researchers continue exploring how individual metabolic differences influence cannabinoid pharmacology, future studies may help clinicians better personalize CBD use while improving the safety of medication management for a broader range of patients.

References:

^{1. Nguyen AHP, Rotich FC, Cech NB, Paine MF, Effects of Simulated Exogenous and Endogenous Lipid Microenvironments on Cannabidiol Disposition and Cytochrome P450 2C19-Mediated Drug Interactions: New Mechanistic Insights, Drug Metabolism and Disposition (2026), doi: https://doi.org/10.1016/j.dmd.2026.100375}